Ibrance boosts effect of HIF2A inhibition in renal cancer

INDICATION: Renal cancer

A team led by William Kaelin Jr., a winner of this year's Nobel Prize in Physiology or Medicine, showed that Ibrance palbociclib, which inhibits CDK4 and CDK6, could enhance the efficacy of HIF2A inhibition in clear cell renal cell carcinoma (ccRCC). In a panel of human ccRCC lines, Ibrance plus an HIF2A inhibitor tool compound reduced growth compared with either agent alone. The combination also prolonged survival and reduced tumor growth in mice with HIF2A-dependent ccRCC. ...